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Neurobiology SelectThe dopaminergic neurons of the central nervous system regulate behavior associated with reward and punish-
ment. Loss of dopamine neurons in the substantia nigra leads to Parkinson’s disease. This issue’s Neurobiology
Select discusses the discovery of a neural circuit involved in decision making in flies and a report showing that
associative learning shifts the timing of dopamine signaling in rodents. Other new work identifies molecular path-
ways that modulate neuronal death in models of Parkinson’s disease suggesting new therapeutic approaches,
including returning mature dopamine neurons to a youthful pattern of neuronal firing.
Making Decisions on the Fly
How does one make a choice when the outcome is uncertain because of
conflicting information? Insight into this vexing problem comes from recent
work by Zhang et al. (2007). They report the identification of a neural circuit in
the fruit fly Drosophila involved in making value-based decisions. Using a
flight simulator, they trained flies to associate a colored bar at a particular
location in its visual field with a punishment, in this case, heat. Having
learned this task, the authors then observed how the flies would behave if
presented with conflicting cues (for instance, a bar in the right place but
the wrong color, or bars with different positions and different intensities).
They found that wild-type flies had strong and distinctive responses to these
dilemmas, whereas mutant flies that had a smaller brain region called the
mushroom body were less choosy in their behavior, even though they were
equally capable of learning the initial training task. The investigators further
characterized the neural circuitry underlying this effect by expressing a tem-
perature-sensitive mutant of the GTPase dynamin in specific neuronal populations to block neuronal function. These
efforts revealed that disruption of dopaminergic neurons had a similar effect on fly behavior as disruption of mush-
room body neurons in these decision-making tasks, suggesting that the two pathways may be connected. Indeed,
immunostaining shows that dopaminergic neurons extensively innervate the mushroom body (see figure). Future
work may establish how these connections are modified by learning and how they mediate decision making.
K. Zhang et al. (2007). Science 316, 1901-1904.
Going from Appreciating to Expecting a Reward
Previous work has proposed that the innervation of the nucleus accumbens
in the brain by midbrain dopamine neurons provides instructive information
enabling prediction of whether a given stimuli will result in a rewarding out-
come. Day et al. (2007) now report the dynamics of dopamine release at
high temporal resolution in the nucleus accumbens in rats learning to associate
a stimulus with a reward. In the learning paradigm used by the authors, rats
were trained to associate the extension of a lever and a light cue with the
delivery 10 s later of a sucrose pellet. Dopamine release wasmonitored directly
by electrochemical recording from precisely positioned electrodes. Early dur-
ing conditioning, before the association between the stimuli and reward had
been established, dopamine release peaked when animals obtained a reward.
However, later during training, this pattern shifted such that the peak in dopa-
mine release came at the time of the presentation of the predictive stimulus and
not the reward. Thus the timing of the reward signal provided by dopamine is
dynamically regulated by associative learning.
J.J. Day et al. (2007). Nat. Neurosci. Published online July 1, 2007. 10.1038/
nn1923.
A New Defender Rallies Dopamine Neurons under Siege
Searching for new factors that might stall the neurodegeneration in Parkinson’s disease, Lindholm et al. (2007) now
report the discovery of CDNF (conserved dopamine neurotrophic factor). CDNF was identified based on its homol-
ogy to another recently characterized protein MANF (mesencephalic astrocyte-derived neurotrophic factor). The
authors tested the ability of CDNF to promote neuronal survival in a rat model of Parkinson’s disease. In this model,
neurodegeneration is triggered by intrastiatal injection of the neurotoxin 6-OHDA, which selectively kills dopaminer-
gic neurons. Their results show that CDNF promotes neuronal survival, even when it is administered 4 weeks after
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6-OHDA injection. This finding is similar to that previously shown for glial cell line-derived neurotrophic factor
(GDNF), which reached phase II clinical trials in Parkinson’s patients. Future workmay establish howCDNFmediates
its neuroprotective and neurorestorative effects. In this regard, the finding that CDNF has orthologues in inverte-
brates might prove advantageous for the rapid discovery of cellular pathways activated downstream of CDNF.
P. Lindholm et al. (2007). Nature 448, 73–77.
A Protective Peroxidase
Previous work has shown that activation of the kinase Cdk5/p35 is a central
mediator of the neurotoxicity caused by MPTP, a neurotoxin that triggers
symptoms of Parkinson’s disease in rodents and humans. MPTP induces
mitochondrial dysfunction, which triggers altered Ca2+ regulation and en-
hanced oxidative stress. In their current work, Qu et al. (2007) identify a crit-
ical substrate of Cdk5/p35 that mediates MPTP toxicity. This substrate is
Prx2, a peroxidase enzyme that eliminates reactive oxygen species. Phos-
phorylation of Prx2 by Cdk5 decreases its enzymatic activity, and conse-
quently neurons lacking Cdk5/p35 are shown to have reduced levels of
reactive oxygen species. Thus, the authors propose a sequence of events
that occur as a consequence of MPTP treatment: an increase in Ca2+ ele-
vates calpain protease activity leading to Cdk5 activation and Prx2 phos-
phorylation, which contributes to an increase in reactive oxygen species
and enhanced neuronal cell death. The authors also observe elevated
Prx2 phosphorylation in postmortem samples from Parkinson’s patients
indicating that a reduction in activity of this peroxidase is likely a characteristic feature of Parkinson’s disease in
humans (see figure). These findings suggest that enhancing Prx2 activity may be a new strategy for the treatment
of Parkinson’s disease.
D. Qu et al. (2007). Neuron 55, 37–52.
Sometimes Juvenile Behavior Should Be Encouraged
Why are the dopaminergic neurons of the substantia nigra particularly susceptible to
degeneration and death? The answer according to Chan et al. (2007) might be related
to their reliance upon Ca2+ channels to support an intrinsic pattern of rhythmic firing
called pacemaking. These authors show that the mechanism by which pacemaking
of dopaminergic neurons of the substantia nigra is maintained changes during devel-
opment, becoming increasingly reliant on the L type Cav1.3 Ca
2+ channels as the neu-
rons mature. Yet, remarkably, adult mice lacking expression of Cav1.3 Ca
2+ channels
retain pacemaking in these dopaminergic neurons through a mechanism that resem-
bles pacemaking in juvenile animals, which is dependent upon Na+ channels. Even
more surprising, the authors then demonstrate that this juvenile form of pacemaking
can be reactivated in adult neurons of wild-type animals following the administration
of isradipine, a Cav1.3 Ca
2+ channel blocker. It has been suggested that excess Ca2+
might be involved in the neurotoxicity of Parkinson’s disease. The authors reasoned
that eliminating the dependence of adult neurons on Ca2+ for pacemaking might
protect them from insults that lead to neuronal death. They tested this hypothesis
and showed that reversion to the juvenile mechanism of pacemaking (which they
call rejuvenation) does indeed protect dopaminergic neurons of the substantia nigra
from three different toxins—rotenone, 6-OHDA, and MPTP—that render rodents
and primates parkinsonian (see figure). The Cav1.3 Ca
2+ channel blocker, isradipine, is already in clinical use for
the treatment of high blood pressure. Future clinical trials combined with analysis of those currently taking the
medication may establish whether isradipine slows the onset and progression of Parkinson’s disease.
C. S. Chan et al. (2007) Nature 447, 1081–1086. Published online June 10, 2007. 10.1038/nature05865.
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